[1]钟 萍.胎儿生长受限的早期诊治[J].医学信息,2019,32(23):58-60.[doi:10.3969/j.issn.1006-1959.2019.23.016]
　ZHONG Ping.Early Diagnosis and Treatment of Fetal Growth Restriction[J].Medical Information,2019,32(23):58-60.[doi:10.3969/j.issn.1006-1959.2019.23.016]
点击复制

胎儿生长受限的早期诊治()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年23期
页码:
58-60
栏目:
综述
出版日期:
2019-12-01

文章信息/Info

Title:
Early Diagnosis and Treatment of Fetal Growth Restriction
文章编号:
1006-1959（2019）23-0058-03
作者:
钟 萍
（桂林医学院第二附属医院产科，广西 桂林 541199）
Author(s):
ZHONG Ping
(Department of Obstetrics，the Second Affiliated Hospital，Guilin Medical College， Guilin 541199，Guangxi，China)
关键词:
胎儿生长受限; 胎儿发育; 母婴结局
Keywords:
Fetal growth restriction; Fetal development; Maternal and child outcomes
分类号:
R714.5
DOI:
10.3969/j.issn.1006-1959.2019.23.016
文献标志码:
A
摘要:
胎儿生长受限（FGR）不仅使胎儿宫内发育落后，而且会影响到胎儿出生后的发育及生活质量。但其病因及生理机制未明，孕早中期对FGR的诊断困难，常在孕晚期才能诊断。因此如何早期预测FGR并对其进行诊疗，以获得较好的母婴结局一直是国内外研究的热点。现将对FGR早期诊断的方法及治疗进展进行综述。
Abstract:
Fetal growth restriction （FGR） is not only the intrauterine growth of the fetus， but also affects the development and life of the fetus after birth. However， its etiology and physiological mechanism are unclear. The diagnosis of FGR in the early and middle trimester is difficult， and it is often diagnosed in the third trimester. Therefore， how to predict FGR early and treat it to obtain better maternal and child outcomes has been a hot topic at home and abroad. This article reviews the early diagnosis methods and treatment progress of fetal growth restriction.

参考文献/References:

[1]谢幸.妇产科学[M].第9版.北京:人民卫生出版社,2018.[2]沈菊芳,钱隽,金秋明.胎儿宫内生长受限的相关因素分析[J].川北医学院学报,2015,30(5):608-610.[3]Whitehead CL,Walker SP,Lappas M,et al.Circulating RNA coding genes regulating apoptosiin maternal blood in severe early onset fetal growth restriction and pre-eclampsia[J].Journal of perinatology:Official journal of the California Perinatal Association,2013,33(8):600-604.[4]陈燕君,周祎.胎儿生长受限的病因[J].中国医刊,2017,52(5):6-9.[5]Baschat AA.Fetal growth restriction from observation to intervention[J].J Perinat Med,2010,38(3):239-246.[6]Royal College of Obstetricians and Gynaecologists.Small-forGestational-Age Fetus, Investigation And Management(Green-top Guideline No.31)[EB/OL].2014-01-22.[7]林洁.妊娠图筛查在产前诊断胎儿生长受限中的意义[J].中国妇幼保健,2015,30(28):4899-4901.[8]Committee on Obstetric Practice.Committee Opinion No 700:Methods for Estimating the Due Date[J].Obstet Gynecol,2017,129(5):e150-e154.[9]安鹏,张敏,王瑜,等.产前超声联合MRI诊断胎儿先天性食管闭锁[J].中国介入影像与治疗学,2018,15(7):429-433.[10]林小琦,何英爱,林志坚,等.彩色超声多血管血流参数监测胎儿宫内生长受限的临床意义表达[J].现代诊断与治疗,2018, 29(18):2864-2866.[11]Copel JA,Bahtiyar MO.A practical approach to fetal growth restriction[J].Obstetrics and Gynecology,2014,123(5):1057-1069.[12]庞振华.彩色多普勒超声对评估孕晚期胎儿生长受限血流情况及预后的应用价值[J].齐齐哈尔医学院学报,2017,38(23):2774-2776.[13]邱燕生,毛羡仪,朱艳芳,等.早中孕期彩色多普勒超声监测子宫螺旋动脉血流在预测胎儿宫内生长受限的应用[J].影像研究与医学应用,2017,1(18):22-23.[14]Guimares Filho HA,Araujo Júnior E,Mattar R,et al.Placental blood flow measured by three-dimensional power Doppler ultrasound at 26 to 35 weeks gestation in normal pregnancies [J].J Matern Fetal Neonatal Med,2010,23(1):69-73.[15]王莹,叶春媚,李燕,等.能量多普勒超声对妊娠高血压综合征患儿胎盘血流动力学的研究[J].中国中西医结合影像学杂志,2015,13(6):623-625.[16]郑毅,胡旭红,徐若梅,等.血管内皮生长因子与妊娠高血压母亲胎儿宫内生长受限的相关性研究[J].中国新生儿科杂志,2015,30(4):268-272.[17]樊秀花,胡艳英,谢有欢,等.母血及脐血中血清蛋白指标水平与胎儿宫内生长受限的关系[J].白求恩军医学院学报,2013, 11(3):214-215.[18]王容,凡伟,黎春梅,等.胎儿生长受限与母血、脐血中锌含量的相关性研究[J].中国妇幼保健,2015,30(23):3978-3979[19]侯倩.超声指标及母血中血清蛋白指标与胎儿宫内生长受限的关系[J].现代诊断与治疗,2016,27(22):4201-4203.[20]方小桂,时雪飞,童芳芳,等.膜联蛋白A5水平检测在妊娠中期胎儿宫内生长受限诊断中的应用研究[J].中国当代医药,2014,21(33):31-32,35.[21]乔文俊.低分子肝素钠在胎儿生长受限治疗中的应用研究[J].中国综合临床,2014,30(3):332-333.[22]王文.必须脂肪酸在胎儿宫内发育迟缓治疗中的作用[J].当代医学,2014,20(13):66-67.[23]李宏志,白雪,李钰,等.产妇孕晚期血清中维生素A、E及微量元素水平及与胎儿生长发育的关系研究[J].中国地方病防治杂志,2018,33(2):175-176.[24]汪萍,单腾飞.低分子肝素联合硫酸镁治疗胎儿生长受限的临床效果及可行性[J].中国妇幼保健,2017,32(17):4171-4173.[25]吴少敏,关灵,郑锐年,等.低分子肝素用于胎儿生长受限临床治疗的效果及其对新生儿结局的影响分析[J].中国实用医药,2017,12(30):124-125.[26]傅兰勇.低分子肝素钠联合小剂量阿司匹林治疗胎儿生长受限疗效分析[J].儿科药学杂志,2018,24(5):15-17.[27]严文彦,卢纹,欧燕珊.胎儿宫内生长受限采用低分子肝素治疗的临床效果分析[J].中国病案,2019,20(2):102-104.

相似文献/References:

[1]沙梦晗,陈素华,亢庆玲,等.低分子肝素治疗胎儿生长受限的临床疗效分析[J].医学信息,2019,32(14):61.[doi:10.3969/j.issn.1006-1959.2019.14.020]
　SHA Meng-han,CHEN Su-hua,Kang Qing-ling,et al.Clinical Analysis of Low Molecular Weight Heparin in the Treatment of Fetal Growth Restriction[J].Medical Information,2019,32(23):61.[doi:10.3969/j.issn.1006-1959.2019.14.020]
[2]张 称,刘 洋.新生儿巨细胞病毒感染的诊断、治疗研究[J].医学信息,2021,34(17):58.[doi:10.3969/j.issn.1006-1959.2021.17.015]
　ZHANG Chen,LIU Yang.Study on the Diagnosis and Treatment of Neonatal Cytomegalovirus Infection[J].Medical Information,2021,34(23):58.[doi:10.3969/j.issn.1006-1959.2021.17.015]
[3]徐欣然,王妍平,刘沙沙.miR-520a-5p在子痫前期及胎儿生长受限中的研究进展[J].医学信息,2024,37(06):171.[doi:10.3969/j.issn.1006-1959.2024.06.032]
　XU Xin-ran,WANG Yan-ping,LIU Sha-sha.Research Progress of miR-520a-5p in Preeclampsia and Fetal Growth Restriction[J].Medical Information,2024,37(23):171.[doi:10.3969/j.issn.1006-1959.2024.06.032]

更新日期/Last Update: 2019-12-01